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Objective: Cognitive impairment is a core feature of schizophrenia, related to dopaminergic dysfunction
in the prefrontal cortex (PFC). It is hypothesized that functional single nucleotide polymorphism (SNP)
rs4680 of the catechol-O-methyltransferase (COMT) gene could mediate the relationship between cogni-
tion and dopamine activity in the PFC. Other COMT SNPs could also play a role.
Methods: We evaluated the role of three COMT SNPs (rs737865, rs165599, and rs4680) in
schizophrenia and their impact on three working memory tasks. For genetic association analyses,
212 individuals with schizophrenia and 257 healthy controls (HCs) were selected. The Visual Working
Memory (VWM) Task, Keep Track Task, and Letter Memory Task were administered to 133 schi-
zophrenics and 93 HCs.
Results: We found a significant association of rs737865, with the GG genotype exerting a protective
effect and the GA haplotype (rs4680/rs165599) exerting a risk effect for schizophrenia. COMT rs4680 AA
carriers and rs737865 AA carriers scored lowest on the Keep Track Task. When the genotype*group
interaction effect was evaluated, rs165599 exerted opposite effects for VWM and Keep Track task
performance in patients and controls, with AA carriers scoring lowest on both tests among controls, but
highest among patients.
Conclusion: These data support the hypothesis that COMT polymorphisms may be associated with
schizophrenia and modulate cognition in patients and controls.
Keywords: Cognition; dopamine; gene
Introduction
Schizophrenia is a multifactorial and debilitating disease
with a high heritability rate (approximately 80%).1 It affects
four to seven people per 1,000 worldwide.2 Despite broad
phenotypic heterogeneity, cognitive impairments have
been considered profound and clinically relevant since
the original descriptions.3 Deficits usually described in
patients involve several cognitive functions, such as
memory, attention, working memory (WM), problem
solving, processing speed, and social cognition.4 Cogni-
tion in schizophrenia has been widely studied in recent
decades, prompted by evidence that it is a determinant of
quality of life and everyday functioning in patients.5
Reduced cognitive performance is already evident at the
first episode of psychosis, which implies that cognitive
dysfunction is a likely neurobiological marker of schizo-
phrenia even before the onset of illness.6,7
The dopamine hypothesis, based on evidence from
pharmacological and in vivo imaging studies, is consid-
ered the final common pathway for psychotic symptoms in
schizophrenia.8 The enzyme catechol-O-methyltransfer-
ase (COMT) metabolizes several catecholamines, but
is especially relevant to dopaminergic transmission
in the prefrontal cortex (PFC), in which it is a key ele-
ment to dopamine availability.9 COMT is encoded by a
single gene (alsoCOMT) located on chromosome 22q11.2,
a region that is commonly missing in 22q11.2 microdeletion
syndrome, which has long been associated with predis-
position for schizophrenia.10 The enzymatic activity of
COMT is altered by a guanine (G) to adenine (A) single
nucleotide polymorphism (SNP) known as Val158Met or
rs4680 in the COMT gene sequence, resulting in a trimodal
distribution (high activity in the Val/Val genotype, inter-
mediate activity in Val/Met, and low activity in Met/Met) and
a three- to four-fold difference in COMT activity (Val/Val vs.
Met/Met).11 Studies on the COMT Val158Met polymorph-
ism and vulnerability to schizophrenia have produced
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conflicting results. Previous meta-analyses do not support
an association between COMT Val158Met and schizo-
phrenia,12-14 whereas one meta-analysis found a small but
significant effect for homozygotes as the risk variant over
heterozygotes in both mixed and Caucasian cohorts.15
Nevertheless, Gatt et al.,16 in a recent review of meta-anal-
yses, highlights that Val vs. Met comparisons were null
when considering larger samples and mixed or Asian
samples.
Cognitive abilities related to the functional integrity of
the frontal lobe and its neural networks throughout the
brain (WM and executive functioning) might be related to
hypodopaminergia in the PFC. Manipulation of dopami-
nergic tone in the PFC is crucial for executive and WM
performance.17 Thus, genetically determined variations in
COMT activity might affect the availability of dopamine in
prefrontal synapses,9 and, thus, affect cognitive abilities,
including WM performance, independently from prone-
ness to schizophrenia.
COMT is one of the most investigated genes in schi-
zophrenia, and its role in cognition has also been studied.
Samples of healthy individuals showed associations,
either positive18,19 or negative, between COMT geno-
types and cognition.20 In schizophrenia samples, there
have also been reports of positive21-23 and negative asso-
ciations.24 In studies that showed positive associations,
schizophrenia patients demonstrated a similar pattern to
healthy controls (HCs): Met (G) homozygotes seem to
have better cognitive performance relative to Val (A)
carriers. A meta-analysis of the cognitive effects of COMT
Val158Met,25 however, concluded that there is weak
evidence of association between this polymorphism and
cognitive function.
Notably, functional variation in the COMT gene is not
limited to the rs4680 SNP, but rather includes other
polymorphisms, such as a P2 promoter region SNP
(rs2097603) and a 30 region SNP (rs165599). These
three SNPs show nonlinear interacting effects on pre-
frontal efficiency during WM task performance, in
agreement with predictions of resultant cortical dopami-
nergic catabolic rates, and highlight the complexity of
genetic contributions to functional neuroimaging pheno-
types, even within a single gene.26 Many studies have
focused on the Val158Met polymorphism, neglecting
other SNPs in the gene. Studies assessing thousands
of SNPs at once, such as genome-wide association
studies (GWAS), need a large sample size, which is limi-
ted by the time-consuming nature of neuropsychological
tests.
Within this context, the aim of this study was to further
investigate the role of three COMT SNPs (rs737865,
rs165599, and rs4680) in schizophrenia and on perfor-
mance in WM tasks in a sample of patients and controls.
Methods
Subjects
A total of 212 patients and 257 HCs were recruited
from Programa de Esquizofrenia (PROESQ) and Labor-
ato´rio Interdisciplinar de Neurocieˆncias Clı´nicas (LiNC),
Universidade Federal de Sa˜o Paulo (UNIFESP), Brazil.
The diagnosis of schizophrenia was confirmed by the
Structured Clinical Interview for DSM-IV applied by trai-
ned psychiatrists. HCs had no family history of severe
psychiatric illness and no current or previous psychiatric
disorders.
All subjects underwent blood collection for genetic
analyses and a sample of 124 patients was assessed with
the Positive and Negative Syndrome Scale (PANSS).
Psychopathological dimensions (negative, positive, exci-
ted, and anxiety/depression) were classified according
to PANSS ratings.27 These individuals had no history of
a diagnosed neurological disorder or medical condition
known to be associated with neuropsychological impair-
ment (e.g., epilepsy, stroke). The UNIFESP Ethics Com-
mittee approved the research protocol, and participants
entered the study only after giving written informed
consent.
DNA isolation and COMT genotyping
Whole blood was collected into tubes containing 0.1%
ethylenediaminetetraacetic acid (EDTA), and genomic
DNA isolation was performed using the Gentra Puregene
Kit (Qiagen, Germantown, United States) according to the
manufacturer’s protocol.
All three COMT polymorphisms (rs737865, rs165599,
and rs4680) were genotyped by TaqMan probe-based
real-time polymerase chain reaction (PCR) assays (Life
Technologies, Foster City, United States) performed
under standard conditions. For each reaction, at least
one positive control for each genotype was included.
Neuropsychological tests
Three tests assessing the ability to update information,
part of WM function, were administered by trained
psychologists to 133 patients and 93 controls. Previous
studies have shown that these tasks are sensible choices
for discriminating the cognitive performance of subjects
with schizophrenia and healthy comparators.28 The IQ of
each participant was also assessed.
In the Visual Working Memory (VWM) task,29 a subject
is asked to pay attention to a computer screen where one
to four 33 matrices are displayed. A stimulus appears
within each matrix for 2 seconds and arrows then start
indicating special manipulations that the subject will be
asked to perform with the stimuli within each matrix. For
example, an arrow pointing to the upward position fol-
lowed by an arrow pointing to the left indicates that the
stimulus should be displaced one row above and one
column to the left from its original position. There is no
time limit for each answer, but the test stops after
consecutive errors. This test was based on the experi-
mental tasks designed by Salthouse et al.30
The Keep Track task, adapted from Yntema,31 first
shows several target categories (animals, colors, coun-
tries, distances, metals, and relatives) on the computer
screen. Then, 15 words are presented verbally in random
order for 1,500 milliseconds each. The target categories
remain on the screen. Each list had two or three exemplars
Rev Bras Psiquiatr. 2017;39(4)
COMT: cognition and schizophrenia 303
from each of the six possible categories. Participants had
to remember the last word presented belonging to the
remaining target categories (the first three trials had four
categories and the last three had five).
The Letter Memory task, adapted from Morris & Jones,32
was the third updating measure. In this task, letters are
presented serially and individually. Participants had to
recall the last two letters presented in each presented list.
However, they had to rehearse the last two letters out
loud by mentally adding the most recent letter, dropping
the third letter back, and then saying the new string of
two letters out loud. This instruction was given to ensure
that participants were performing continuous updating.
Although previous studies have used sequences ranging
from four to nine words, we had to define this length
because most of the patients could not start performance
with larger sequences.
For all three tests, higher values denote better perfor-
mance.
Statistical analysis
First, Hardy-Weinberg equilibrium (HWE) was verified
using the chi-squared test. For cognitive analysis, we
used square root transformation. To associate each
genotype and allele to schizophrenia, we used logistic
regression. Then, we constructed a general linear model
(GLM) using each cognitive variable as a dependent
variable, genotypes of each SNP and group (patient or
control) as independent variables, and IQ as covariate to
explore SNP and group effects on cognitive variables
individually or their interaction (genotype*group), investi-
gating whether the association of each genotype with the
relevant dependent variable differed between cases and
controls. Linkage disequilibrium (LD) was assessed with
SNP Stats33 (http://bioinfo.iconcologia.net/snpstats/start.
htm?) and haplotypes were estimated using PLINK. To
test for association between haplotypes and schizophre-
nia, we performed logistic regression, and for association
between haplotypes and cognitive variables, we used a
GLM, considering haplotypes and groups as independent
variables and IQ as covariate, with the Bonferroni post-
hoc procedure. We also investigated the haplotype*group
interaction effect on cognitive variables.
Results
The clinical and demographic characteristics of the study
population are described in Tables 1 and 2. No differences
in gender, age, ethnicity, handedness, or education were
found between cases and controls.
Association between COMT SNPs and schizophrenia
Allele and genotype frequencies for each group, as well
as p-values for HWE, are described in Supplementary
Table 1 (online-only). Only rs737865 genotype distribu-
tion in the patient group deviated from HWE (p = 0.001).
However, when combining schizophrenia and control
Table 1 Characteristics of the study population
Schizophrenia Control
Variable N n N n p-value
Gender 212 257
Male 146 158 0.095
Female 66 99
Ethnicity 198 239
Caucasian 116 160 0.071
Non-Caucasian 82 79
Handedness 131 92
Right 122 86 0.919
Left 9 6
Variable N Mean (SD) N Mean (SD) p-value
Age (years) 212 36.03 (10.61) 257 37.12 (12.19) 0.301
Education (years) 131 10.83 (3.14) 92 11.41 (2.56) 0.130
SD = standard deviation.
Table 2 Characteristics of the schizophrenia group
Variable N Mean (SD)
Age at onset (years) 127 22.65 (6.53)
Duration of illness (years) 105 15.31 (9.01)
PANSS - negative symptoms 124 24.25 (7.11)
PANSS - positive symptoms 123 16.65 (5.75)
PANSS - excited 123 7.22 (2.38)
PANSS - anxiety/depression 124 9.22 (3.31)
PANSS = Positive and Negative Syndrome Scale; SD = standard deviation.
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groups, no significant deviation from HWE was found
(p = 0.087); hence, this polymorphism was included in our
analyses.
Using logistic regression, we found a significant asso-
ciation between COMT rs737865 genotypes and schizo-
phrenia (p = 0.017). Considering the AA genotype as
reference, the GG genotype seemed to exert a pro-
tective effect (p = 0.034; odds ratio [OR] = 0.200; 95%
confidence interval [95%CI] = 0.045-0.884). However, we
did not observe a significant association between rs737865
alleles and schizophrenia (p = 0.926). For the other SNPs,
we did not find significant associations between genotypes
(rs4680: p = 0.702; rs165599: p = 0.348) or alleles (rs4680:
p = 0.583; rs165599: p = 0.155) and schizophrenia.
Haplotype analysis showed that rs4680 and rs737865
SNPs were in moderate LD (D0 = 0.715), as were rs4680
and rs165599 (D0 = 0.604). On the other hand, rs737865
and rs165599 showed a weak LD (D0 = 0.083). There-
fore, only haplotype blocks constructed with rs4680 and
rs737865 or those constructed with rs4680 and rs165599
were considered for the analyses. Haplotype frequen-
cies are described in Supplementary Table 2 (online-only).
We found a significant association between G-A (rs4680/
rs165599) haplotype and schizophrenia compared to G-G
haplotype (p = 0.014; OR = 1.64; 95%CI = 1.11-2.42). No
significant association between haplotype blocks con-
structed with rs4680 and rs737865 and schizophrenia was
found.
Association between COMT SNPs and WM
The main effects when comparing cognitive variables and
groups or genotypes are described in Table 3. We found a
significant decrease in all three WM task scores (VWM,
Keep Track, and Letter Memory) in patients when com-
pared to controls (Table 3). Analyzing the association
between SNPs and cognitive variables, we found a signi-
ficant association between rs4680 and Keep Track task
scores (Table 3), with AA (Val/Val) subjects performing
worse than GG (Met/Met) subjects (post-hoc Bonferroni
p = 0.042). The same association was identified for
rs737865, with AA carriers performing worse than GG
carriers for the Keep Track task (post-hoc Bonferroni
p = 0.043). However, when the interaction between these
SNPs and group (genotype*group) was analyzed, we did
not find a significant association (Table 3).
Although rs165599 was not associated with any of the
cognitive variables, considering the interaction genotype*
group, there was a significant difference (Table 3 and
Figure 1), with AA carriers performing worse in the control
group and GG carriers performing worse in the patient
group for both the VWM and Keep Track tasks.
Comparing haplotypes and cognitive variables, we
found a significant association with Keep Track Task per-
formance (p = 0.017), showing that G-A (rs4680/rs165599)
(mean = 3.89; standard deviation [SD] = 0.49) subjects had
higher scores than A-A carriers (mean = 3.74; SD = 0.51)
(post-hoc Bonferroni p = 0.043). Moreover, haplotype
blocks with rs737865 and rs4680 were also associa-
ted with Keep Track Task performance (p = 0.040),
with A-A (rs737865/rs4680) carriers performing worseT
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(mean = 3.76; SD = 0.51) than G-G haplotype carriers
(mean = 3.92; SD = 0.53) (post-hoc Bonferroni p = 0.034).
All p-values comparing haplotypes and each cogni-
tive variable are described in Supplementary Table 3
(online-only).
Discussion
In this study, we evaluated the association between three
COMT SNPs and the diagnosis of schizophrenia and
cognitive performance on WM tasks. We found a sig-
nificant association between rs737865 genotypes and
schizophrenia, with the GG genotype exerting a protec-
tive effect and GA a risk effect. In a large study of an
Israeli Ashkenazi Jewish population, Shifman et al.34
reported that the polymorphisms rs737865 and rs165599
were highly associated with the disease, suggesting that
more than one functional polymorphism should affect
susceptibility to schizophrenia at the COMT locus. For the
other SNPs, we did not find associations on comparisons
of genotypes and alleles individually, similarly to previous
studies in Brazilian35 and Greek36 populations.
When analyzing the haplotypes constructed with
rs4680 and rs165599 SNPs, we did find a significant
association, with the G-A haplotype (rs4680/rs165599)
being a risk factor for schizophrenia when compared to
the G-G haplotype. According to the literature, several
haplotypes instead of individual alleles may be associated
with schizophrenia due to differences in LD among
populations.37 Previous studies have implicated associa-
tions of the rs4680/rs165599 haplotypes with schizophre-
nia and reported an effect opposite from that observed in
our sample, with G-G (rs4680/rs165599) and A-G-G
(rs737865/rs4680/rs165599) being the risk haplotypes
and G-G-A (rs737865/rs4680/rs165599) the protective
haplotype.34,36,38 Both SNPs seem to exert a functional
effect, since rs4680 has an effect on COMT activity and
rs165599 has an impact on COMT expression.39 Clinical
studies of COMT have revealed that the Met allele (G)
was associated with better performance on tests of
prefrontally mediated cognition.22,23,40-42 Moreover, in a
postmortem human brain study, Chen et al.43 demon-
strated that Val (A) is a predominant factor that
determines higher COMT activity, which results in lower
prefrontal dopamine signaling and, by this mecha-
nism, leads to relatively impaired prefrontal cortical func-
tion. Hence, we could hypothesize that the G/Met-allele
(rs4680), which induces a low activity, in combination with
the G-allele (rs165599), which leads to reduced expres-
sion of COMT,39 might exert a protective effect, explain-
ing the higher frequency of the G-G haplotype in controls
than in patients in our sample.
Regarding the cognitive variables, patients performed
worse in all three WM tests (VWM, Keep Track Task and
Letter Memory Task), and COMT SNPs might be
influencing cognitive performance. We found that both
rs4680 and rs737865 seem to be associated with Keep
Track Task performance, independently of group status
(i.e., schizophrenia or HC), with AA carriers (for either
rs4680 or rs737865) scoring lowest. This result is in line
with previous studies that reported positive results in both
healthy and schizophrenia samples.18,19,21-23 This asso-
ciation seems to be even stronger in the haplotype
analysis, with a similar effect, i.e., A-A carriers (A allele
of rs4680; A allele of rs165599) scoring lower than
G-A carriers (G allele of rs4680; A allele of rs165599).
A similar effect was found for haplotypes constructed
with rs737865 and rs4680, with A-A haplotype carriers
(A allele of rs737865; A allele of rs4680) scoring lower
than G-G- carriers (G allele of rs737865; G allele of
rs4680). Our results are consistent with those of Meyer-
Lindenberg et al.,26 who demonstrated how haplotype
analysis should be superior in predicting WM task
performance and prefrontal function. When we evaluated
the genotype*group interaction, rs165599 exerted oppo-
site effects for VWM and Keep Track Task performance in
patients and controls: AA carrier status was associated
with the lowest scores for both tests in controls, but the
highest scores in patients (Figure 1).
Our study has limitations that must be considered.
First, the sample size was small and statistical power
was weak, especially for a genetic association study; how-
ever, we analyzed cognitive data, which limited the number
of participants assessed. Despite selecting 212 patients
with schizophrenia and 257 HCs, only 133 patients and
93 HCs underwent cognitive testing, due to logistic issues.
Nevertheless, our sample has power to support that the
COMT polymorphisms may be associated to schizophrenia
Figure 1 Interaction effect between group and rs165599, which was significant for both Visual Working Memory (VWM) Task
and Keep Track Task.Scores presented as square roots.
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diagnosis and modulate cognitive performance in both,
people with schizophrenia and healthy subjects. Second,
the effect sizes were small, which is a common limitation of
gene association studies. Further studies should be
performed with larger samples. Finally, we acknowledge
that the role of COMT in schizophrenia has been widely
investigated in past decades, and that the heterogeneity of
past research and complexity of schizophrenia phenotypes
must be taken into consideration for our conclusions.
Our results are consistent with the major role of COMT
in modulating dopamine flux in the PFC and its associa-
tion with schizophrenia and cognitive function. Regarding
this association with the disorder, we found a significant
effect of rs737865 genotypes in schizophrenia and of
rs4680/rs165599 haplotypes, with an effect opposite to
that observed in European populations. The effect of
individual SNPs on cognition was supported by previous
studies, indicating a worse performance of A-allele
genotypes and haplotypes of rs4680 on WM tasks. In
addition, the GG genotype and G-allele haplotypes of
rs737865 seemed to exert a protective effect on risk of
schizophrenia and be associated with higher scores on
the Keep Track Task. An interaction effect was also found
for group*rs165599, showing the importance of investi-
gating both patients and healthy subjects.
This was the first association study to analyze COMT
haplotypes and cognition in a Brazilian sample of patients
with schizophrenia. The significance of our positive find-
ings encourages further investigations.
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